Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0120 in Refractory Systemic Lupus Erythematosus
NCT06897930Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2025
- Primary completion
- May 2029
- Modality
- CAR-T Cells
- Countries
- 4
01
Overview
A Phase 2 trial of GC012 in systemic lupus erythematosus (SLE), sponsored by AstraZeneca. Started Apr 2025; status: recruiting.
02
Drugs
GC012
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06897930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06897930.